Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
01 2019
Historique:
received: 19 09 2018
revised: 13 11 2018
accepted: 15 11 2018
pubmed: 27 11 2018
medline: 17 7 2019
entrez: 27 11 2018
Statut: ppublish

Résumé

Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leukemia patients further supports the importance of a minimally deleted region composed of seven genes potentially involved in leukemogenesis: GKAP1, KIF27, C9ORF64, HNRNPK, RMI1, SLC28A3 and NTRK2. Importantly, among them HNRNPK, encoding heterogeneous nuclear ribonucleoprotein K is proposed to function in leukemogenesis. We show that expression of HNRNPK and the other genes of the minimally deleted region is significantly reduced in patients with del(9q) compared with normal karyotype acute myeloid leukemia. Also, two mRNAs interacting with heterogeneous nuclear ribonucleoprotein K, namely CDKN1A and CEBPA are significantly downregulated. While the deletion size is not correlated with outcome, associated genetic aberrations are important. Patients with an additional t(8;21) show a good prognosis. RUNX1-RUNX1T1, which emerges from the t(8;21) leads to transcriptional down-regulation of CEBPA. Acute myeloid leukemia patients with mutations in CEBPA have a good prognosis as well. Interestingly, in del(9q) patients with CEBPA mutation mRNA levels of HNRNPK and the other genes located in the minimally deleted region is restored to normal karyotype level. Our data indicate that a link between CEBPA and the genes of the minimally deleted region, among them HNRNPK contributes to leukemogenesis in acute myeloid leukemia with del(9q).

Identifiants

pubmed: 30476680
pii: S0145-2126(18)30468-5
doi: 10.1016/j.leukres.2018.11.007
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
CCAAT-Enhancer-Binding Proteins 0
CEBPA protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-23

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Isabel S Naarmann-de Vries (IS)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany. Electronic address: inaarmann@ukaachen.de.

Yvonne Sackmann (Y)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany.

Felicitas Klein (F)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany.

Antje Ostareck-Lederer (A)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany.

Dirk H Ostareck (DH)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany.

Edgar Jost (E)

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany.

Gerhard Ehninger (G)

Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany.

Tim H Brümmendorf (TH)

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany.

Gernot Marx (G)

Department of Intensive Care Medicine, University Hospital RWTH Aachen University, Aachen, Germany.

Christoph Röllig (C)

Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany.

Christian Thiede (C)

Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany.

Martina Crysandt (M)

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany. Electronic address: mcrysandt@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH